Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy

Learn more about:
Related Clinical Trial
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

Recurrence After Whipple's (RAW)

Official Title

An International Multi-centre Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma, Ampullary Adenocarcinoma and Distal Bile Duct Cholangiocarcinoma

Brief Summary

      Pancreatic head malignancies are aggressive cancers that are often inoperable when they are
      diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable,
      surgery is the only treatment that can provide a chance of cure. Unfortunately, up to 75% of
      patients undergoing surgery will have the cancer come back (recur). One of the reasons for
      this is the challenge of removing the whole tumour with some surrounding non-cancerous tissue
      to ensure that every tumour cell has been removed. This is difficult because there are many
      structures very close to the pancreas (such as the blood vessels that supply the intestines)
      that cannot be removed. A recent review study of >1700 patients who had a Whipple's operation
      (the cancer operation that is performed to remove the head of pancreas) and found that whilst
      the majority of patients had cancer recurrence in distant sites (like the liver) that would
      not be affected by how the operation was performed, 12% of patients had the cancer recur just
      at the site of where the operation had been; this is known as 'local' recurrence. This
      suggests that a small amount of cancer was not removed at the time of surgery in these
      patients. Very few studies have looked at the relationship between the Computerised
      Tomography (CT) scan before surgery and the histology results (information about the tumour
      after it has been examined under the microscope) and whether this can predict exactly where
      the tumour recurs. If investigators can find factors that predict which patients get local
      only recurrence, investigators may be able to offer improved surgical techniques or other
      therapies during or immediately after the operation to these patients, hopefully leading to
      improved cure rates.

      This retrospective international study will look at these factors in patients who underwent a
      Whipple's operation for pancreatic cancer, bile duct cancer or ampullary cancer over a five
      year period between 2010 and 2015. Hospitals in eight countries will provide data on
      pre-operative scans, complications around the time of surgery, any therapies (e.g.
      chemotherapy) that the patients had and if and where the cancer recurred. With this
      information, investigators hope to find ways to predict which patients will get local-only
      recurrence, so investigators can select them for additional treatments to improve the chance
      of cure from surgery.
    

Detailed Description

      Research window:

      This retrospective observational cohort study will investigate the outcomes of patients who
      underwent pancreaticoduodenectomy at 30 hepatopancreaticobiliary (HPB) surgery centres in the
      UK and abroad between 01/06/2010 and 31/05/2015. These dates were chosen because:

        -  Most HPB units would expect to see 30-50 patients undergoing pancreaticoduodenectomy per
           annum. Based on the chief investigator's unit's prospectively maintained database of
           consecutive patients, 310 patients underwent pancreaticoduodenectomy during this window
           (benign and malignant). A five year research window would provide a large number of
           patients that is appropriate for subset analysis. This is especially important in distal
           cholangiocarcinoma, which is less commonly treated with pancreaticoduodenectomy compared
           to pancreatic and ampullary cancer. Even if all centres only provided 100 patients (20
           per annum), this would provide a cohort of ~3000 patients. This number of cases will
           have greater resolution to detect small but significant statistical differences in
           studied variables.

        -  The amount of data available on patient records reduces with chronicity, in part due to
           a heavier reliance on paper rather than digital records. In addition, other reporting
           standards (e.g. TNM staging and histology reporting) change over time. 2010 was selected
           as a starting year as the 7th edition of the UICC TNM staging came into effect that
           year.

        -  An end date of June 2015 allows the study to collect full five-year follow up data on
           all patients to June 2020, thus providing a complete data set.

      Data collection:

      Data will be collected by each participating centre on a purpose-built REDCap database.
      REDCap is a well-established secure web-based data collection tool that is frequently used in
      medical research involving several centres. Advantages include:

        -  Real-time collection of data from all centres visible to the research team.

        -  Guaranteed anonymity of patients as only anonymised data will be collected.

        -  In-built data validation (e.g. set limits on expected ranges of values) to reduce poor
           quality/erroneous data collection.

        -  Easy download of data into a format suitable for processing on an appropriate
           statistical software package (e.g. SPSS).

        -  The ability to display or hide questions based on previous responses to tailor data
           collection to each record.

      REDCap access is provided through University Hospitals Plymouth NHS Trust (UHPNT). Data is
      stored on the Microsoft Azure web-based cloud service. Servers are based in the EU and are
      GDPR compliant. REDCap access will be provided to all participating centres (one user log in
      per centre) for data collection.

      Data collected falls into the following categories (examples given after each category are
      not exhaustive):

        -  Participant ID number (anonymised).

        -  Demographics: Age, sex, body mass index.

        -  Comorbidities: Diabetes, cardiovascular disease, respiratory disease, previous history
           of cancer.

        -  Pre-operative imaging: Dates, modalities, maximum tumour size, radiological TNM stage.

        -  Pre-operative biliary drainage: Approach, stent type.

        -  Neoadjuvant therapies: Type, duration.

        -  Pre-operative bilirubin.

        -  Surgery: Date, type, ASA grade, intraoperative procedures and findings.

        -  Post-operative complications: Types, date of occurrence, Clavien-Dindo grade, treatment,
           30-day readmission, 90-day mortality and cause of death.

        -  Histology: Cancer type, differentiation, tumour size, pathological TNM stage, R status,
           involved margins and distance, total and involved number of resected lymph nodes,
           perineural, microvascular and named vessel invasion.

        -  Adjuvant therapies: Type, duration.

        -  Recurrence: Date of recurrence, site(s) of recurrence.

        -  Palliative therapies: Type, duration.

        -  Survival: Disease free survival (DFS) and overall survival (OS).

      Screening of eligible patients:

      Patients will be screened to ensure that they meet the inclusion and exclusion criteria (see
      below). Each unit will be responsible for screening patients for eligibility. All
      participating units have confirmed that they already have an existing list of consecutive
      patients who underwent PD during the research window. The clinical team at each participating
      unit will be responsible for maintaining a password-protected participant look up database
      that links the local patient hospital number to the anonymised participant ID number on
      REDCap.

      Plymouth sub-study on sarcopenia and myosteatosis:

      There is evidence that sarcopenia and myosteatosis may indicate a higher risk of
      postoperative complications, although its impact on DFS and OS is not yet established.
      Patients entered into the study from Plymouth will also have their pre-operative CT scan
      reviewed by a member of the research team trained in sarcopenia and myosteatosis estimation
      (an academic radiology trainee). The clinicians taking the measurements will be unaware of
      any outcomes or complications.

      This is not being extended to other centres for the following reasons:

        -  Normal values of tissue attenuation are specific to local populations due to the
           variation in morphology of patients and the HU cut-offs in one country are not
           applicable to other countries. It would therefore not be possible to pool data on
           myosteatosis and sarcopenia from multiple countries.

        -  As the measurement relies on pre-operative CT imaging, and CT scanners and protocols
           vary between hospitals and change over time, it is difficult to retrospectively pool
           such data from multiple sites and maintain meaningful data. Using a single centre
           provides more robust data for analysis.

        -  The investigators will be using an inbuilt software package that is part of Plymouth's
           InSightWeb. This package may not be available in other centres.

      As this reduces the number of patients in the cohort, Plymouth will extend its research
      window to 01/05/2006. This date was chosen as it is the beginning of their prospectively
      maintained database. This provides a pre-screened population of 365 patients who underwent PD
      at our unit, with a predicted 276 patients for analysis.
    


Study Type

Observational


Primary Outcome

Patterns of disease recurrence

Secondary Outcome

 Determine if/how morbidity, mortality, disease free survival (DFS) and overall survival (OS) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:

Condition

Pancreatic Cancer

Intervention

Pancreaticoduodenectomy

Study Arms / Comparison Groups

 Pancreatic ductal adenocarcinoma
Description:  Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

3000

Start Date

October 12, 2020

Completion Date

March 30, 2022

Primary Completion Date

September 30, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Patients who underwent pancreaticoduodenectomy for pancreatic head malignancy.

          -  Date of surgery from 01/06/2010* to 31/05/2015 inclusive (*01/05/2006 for Plymouth
             sub-study).

          -  Post-operative surgical histology confirmed pancreatic ductal adenocarcinoma (PDAC),
             ampullary adenocarcinoma (AA) or distal bile duct cholangiocarcinoma (DBCC).

        Exclusion Criteria:

          -  Postoperative surgical histology confirmed benign pathology, non-invasive neoplasia or
             malignant tumours other than adenocarcinoma of pancreatic, ampullary or biliary
             origin.

          -  Patients who underwent distal pancreatectomy or total pancreatectomy as their primary
             procedure.

          -  Patients in whom five-year follow up data is not available.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Somaiah Aroori, +44-1752-432-824, [email protected]

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT04596865

Organization ID

20/GAS/413


Responsible Party

Sponsor

Study Sponsor

University Hospital Plymouth NHS Trust

Collaborators

 University of Plymouth

Study Sponsor

Somaiah Aroori, Principal Investigator, University Hospitals Plymouth NHS Trust


Verification Date

October 2020